Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 10929035)

1.

Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome.

Wu XL, Long D, Yu L, Yang JH, Zhang YC, Geng F.

World J Emerg Med. 2013;4(3):190-5. doi: 10.5847/wjem.j.1920-8642.2013.03.006.

2.

The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.

O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP.

Theranostics. 2013 Jun 25;3(7):496-506. doi: 10.7150/thno.4953. Print 2013. Review.

4.

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Balakumaran A, Robey PG, Fedarko N, Landgren O.

Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Review.

5.

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Purushothaman A, Chen L, Yang Y, Sanderson RD.

J Biol Chem. 2008 Nov 21;283(47):32628-36. doi: 10.1074/jbc.M806266200. Epub 2008 Sep 23.

6.

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.

Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noël A, Van Marck E, Van Riet I, Van Camp B, Vanderkerken K.

Br J Cancer. 2002 Mar 4;86(5):796-802.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk